<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32186</article-id><article-id pub-id-type="doi">10.17116/terarkh201789526-32</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Chronic stress and mental disorders in patients with systemic scleroderma: Results of an interdisciplinary study</article-title><trans-title-group xml:lang="ru"><trans-title>Хронические стресс и психические расстройства у больных системной склеродермией: результаты междисциплинарного исследования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Seravina</surname><given-names>O F</given-names></name><name xml:lang="ru"><surname>Серавина</surname><given-names>О Ф</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lisitsyna</surname><given-names>T A</given-names></name><name xml:lang="ru"><surname>Лисицына</surname><given-names>Т А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Starovoytova</surname><given-names>M N</given-names></name><name xml:lang="ru"><surname>Старовойтова</surname><given-names>М Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Desinova</surname><given-names>O V</given-names></name><name xml:lang="ru"><surname>Десинова</surname><given-names>О В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kovalevskaya</surname><given-names>O B</given-names></name><name xml:lang="ru"><surname>Ковалевская</surname><given-names>О Б</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Veltishchev</surname><given-names>D Yu</given-names></name><name xml:lang="ru"><surname>Вельтищев</surname><given-names>Д Ю</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГБУ «Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П. Сербского» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2017-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2017</year></pub-date><volume>89</volume><issue>5</issue><issue-title xml:lang="en">VOL 89, NO5 ()</issue-title><issue-title xml:lang="ru">ТОМ 89, №5 (2017)</issue-title><fpage>26</fpage><lpage>32</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2017, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2017, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32186">https://ter-arkhiv.ru/0040-3660/article/view/32186</self-uri><abstract xml:lang="en"><p>Aim. To analyze of the prevalence of stressful factors and mental disorders (MDs), as well as their clinical psychopathological and clinical psychological characteristics to improve the comprehensive diagnosis and treatment of systemic scleroderma (SSD). Subjects and methods. Examinations were performed in 110 patients (predominantly women (n=97 (88.2%); mean age, 49.9±2.47 years) with a documented diagnosis of SSD (its mean duration, 7.25±0.42 years). 62 (56.4%) patients had limited SSD, 36 (32.7%) had diffuse SSD, and 12 (10.9%) had overlap syndrome. The disease was rapidly and slowly progressive in 33 (30%) and 77 (70%) patients, respectively. Oral glucocorticosteroids were used in 99 (90%) patients included in the study, cytotoxic drugs in 66 (60%), plaquenil in 33 (30%); 8 (7%) patients were treated with the biological agent rituximab. All the patients were examined by a psychologist and a psychiatrist. The psychopathological diagnosis of MD was made during a semistructured interview in accordance with the ICD-10 criteria. The Montgomery-Asberg depression and Hamilton anxiety rating scales were used to evaluate the severity of depression and anxiety, respectively. All patients underwent a clinical and psychological examination, including tests assessing memory, attention, and logical thinking, as well as projective techniques. Results. MDs were detected in 91 (83%) patients with SSD. There was a preponderance of depressive disorders in 74 (67.3%) patients: chronic (dysthymia in 33 (30%) patients)) and recurrent (recurrent depressive disorder in 34 (31%)) depressions. Cognitive impairment (CI) of varying severities was diagnosed in 100% of the patients. Schizotypal personality disorder was stated in 44 (40%) patients. 90% of patients were found to have chronic psychic traumas mainly as parental deprivation in childhood (in children less than 11 years of age). 76.7% of the SSD cases developed recurrent episodes of depression in the presence of long-term MD or had a history of the episodes. There was no relationship of MD to gender, age, duration of SSD and its individual clinical manifestations. The nature of SSD treatment did not affect the frequency and spectrum of MD. Conclusion. MDs, predominantly chronic and recurrent depression, and CI are characteristic of most SSD patients. Multiple chronic stressful factors, both previous SSD and those over time, have commonly an impact on the mental health of patients with SSD</p></abstract><trans-abstract xml:lang="ru"><p>Резюме Цель исследования. Анализ распространенности психотравмирующих факторов и психических расстройств (ПР), а также их клинико-психопатологических и клинико-психологических особенностей для улучшения комплексной диагностики и повышения качества лечения больных системной склеродермией (ССД). Материалы и методы. Обследовали 110 пациентов с достоверным диагнозом ССД, преимущественно женщины — 97 (88,2%), средний возраст которых составил 49,9±2,47 года, средняя длительность ССД—7,25±0,42 года. У 62 (56,4%) пациента имелась лимитированная, у 36 (32,7%) — диффузная форма ССД и у 12 (10,9%) — перекрестный синдром. У 33 (30%) пациентов было быстро прогрессирующее, у 77 (70%) — медленно прогрессирующее течение заболевания. Глюкокортикостероиды внутрь получали 99 (90%) пациентов, вошедших в исследование, цитотоксические препараты — 66 (60%), плаквенил — 33 (30%), лечение генно-инженерным биологическим препаратом ритуксимаб — 8 (7%). Все пациенты обследованы психологом и психиатром. Психопатологическая диагностика ПР проводилась в ходе полуструктурированного опроса по критериям МКБ-10. Для оценки выраженности депрессии использовали шкалу депрессии Монтгомери—Асберг, тревоги — шкалу тревоги Гамильтона. Всем пациентам проводили клинико-психологическое обследование, включающее методики оценки памяти, внимания, логического мышления и проективные методики. Результаты. ПР выявлены у 91 (83%) пациента с ССД. Преобладали депрессивные расстройства — у 74 (67,3%): депрессии с хроническим (дистимия у 33, или 30%) и рекуррентным течением (рекуррентное депрессивное расстройство у 34, или 31%). Когнитивные нарушения различной степени выраженности диагностированы у 100% пациентов. У 44 (40%) пациентов констатировано шизотипическое расстройство. У 90% больных выявлены хронические психические травмы в детском возрасте (до 11 лет), преимущественно в виде родительской депривации. В 76,7% случаев ССД развивалась на фоне длительного ПР или же в анамнезе отмечались повторные эпизоды депрессии. Не отмечено связи ПР с полом, возрастом, длительностью и отдельными клиническими проявлениями ССД. Характер терапии ССД не влиял на частоту и спектр ПР. Заключение. ПР, преимущественно хронические и рекуррентные депрессии, а также когнитивные нарушения характерны для большинства больных ССД. Для пациентов с ССД характерно влияние множественных хронических стрессовых факторов, как предшествующих ССД, так и в ее динамике.</p></trans-abstract><kwd-group xml:lang="en"><kwd>systemic scleroderma</kwd><kwd>mental disorders</kwd><kwd>depression</kwd><kwd>cognitive impairment</kwd><kwd>chronic stressful factors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>системный склероз</kwd><kwd>психические расстройства</kwd><kwd>депрессия</kwd><kwd>когнитивные нарушения</kwd><kwd>хронические психотравмирующие стрессовые факторы</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ревматология: клинические рекомендации. Под ред. акад. РАМН Е.Л. Насонова. 2-е изд. испр. и доп. М.: ГЕОТАР-Медиа; 2010:523-557.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Cutolo M, Straub RH. Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodulation. 2006;13(5-6): 277-282. doi:10.1159/000104855</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Сhen Y, Huang JZ, Qiang Y, Wang J, Han MM. Investigation of stressful life events in patients with systemic sclerosis. J Zhejiang Univ Sci B. 2008;9(11):853-856. doi:10.1631/jzus.B0820069</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Vasile M, Valesini G, Riccieri V. Acute Stress: Is it a Risk Factor for the Development of Systemic Sclerosis? Ann Rheum Dis. 2015;74:1137. doi:10.1136/annrheumdis-2015-eular.6067</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Лисицына Т.А., Вельтищев Д.Ю., Краснов В.Н., Насонов Е.Л. Клинико-патогенетические взаимосвязи иммуновоспалительных ревматических заболеваний и психических расстройств. Клиническая медицина. 2014;92(1):12-20.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Roca RP, Wigley FM, White B. Depressive symptoms associated with scleroderma. Arthrit Rheum. 1996;39(6):1035-1040. doi:10.1002/art.1780390623</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Waheed A, Hameed K, Khan AM, Syed JA, Mirza AI. The burden of anxiety and depression among patients with chronic rheumatologic disorders at a tertiary care hospital clinic in Karachi, Pakistan. J Pak Med Assoc. 2006;56(5):243-246.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Thombs BD, Hudson M, Taillefer SS, Baron M. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. Arthrit &amp; Rheum. 2008;59(4):504-509. doi:10.1002/art.23524</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mozzetta A, Antinone V, Alfani S, Neri P, Foglio Bonda PG, Pasquini P, Puddu P, Picardi A. Mental health in patients with systemic sclerosis: a controlled Investigation. J Eur Acad Dermatol Venereol. 2008;22(3):336-340. doi:10.1111/j.1468-3083.2007.02426.x</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Mura G, Krishna M Bhat, Pisano A, Licci G, Carta M. Psychiatric Symptoms and Quality of Life in Systemic Sclerosis. Clinical Practice &amp; Epidemiology in Mental Health. 2012;8(1):30-35. doi:10.2174/1745017901208010030</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Baubet T., Ranque B, Taïeb O, Bérezné A, Bricou O, Mehallel S, Moroni Ch, Belin C, Pagnoux Ch, Moro M, Guillevin L, Mouthon L. Mood and anxiety disorders in systemic sclerosis patients. Presse Med. 2011;40:e111-e119. doi:10.1016/j.lpm.2010.09.019</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Baubet T, Brunet M, Garcia De La Peña-Lefebvre P, Taïeb O, Moro MR, Guillevin L, Mouthon L. Psychiatric manifestations of systemic sclerosis. Ann Med Interne. 2002;153(4):237-341.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Matsuura E, Ohta A, Kanegae F, Haruda Y, Ushiyama O, Koarada S, Togashi R, Tada Y, Suzuki N, Nagasawa K. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol. 2003;30:1782-1787.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Beretta L, Astori S, Ferrario E, Caronni M, Raimondi M, Scorza R. Determinants of depression in 111 Italian patients with systemic sclerosis. Reumatismo. 2006;58(3):219-225. doi:10.4081/reumatismo.2006.219</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Thombs BD, Taillefer SS, Hudson M, Baron M. Depression in patients with systemic sclerosis: A systematic review of the evidence. Arthrit Rheum. 2007;57(6):1089-1097. doi:10.1002/art.22910</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Thombs BD, Fuss S, Hudson M, Schieir O, Taillefer SS, Fogel J, Ford DE, Baron M. High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. Arthrit Rheum. 2008;59(3):431-437. doi:10.1002/art.23328</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, Boling Ch, Reed J, White B, Wigley FM. The impact of pain and symptoms of depression in scleroderma. Pain. 2002;95(3):267-275. doi:10.1016/s0304-3959(01)00409-2</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Danieli E, Airò P, Bettoni L, Cinquini M, Antonioli Ch.M., Cavazzana I, Franceschini F, Cattaneo R. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol. 2005;24:48-54. doi:10.1007/s10067-004-0970-z</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bell C, Coupland N, Creamer P. Digital infarction in a patient with Raynaud’s phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report. Angiology. 1996;47:901-903. doi:10.1177/000331979604700909</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM. Treatment of Raynaud’ s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology Oxford. 2001;40(9):1038-1043. doi:10.1093/rheumatology/40.9.1038</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Hannestad J, Della Gioia N, Bloch M. The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis. Neuropsychopharmacology. 2011;36 (12):2452-2459. doi:10.1038/npp.2011.132</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Masi AT. Subcommittee for scleroderma criteria of the American Rhеumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rhеum. 1980;23(5):581-590. doi:10.1002/art.1780230510</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Jordan S, Maurer B, Toniolo M, Michel B, Distler O. Performance of the new EULAR /ACR classification criteria for systemic sclerosis in clinical practice. Ann Rhеum Dis. 2013;72(Suppl.3):60. doi:10.1136/annrheumdis-2013-eular.239</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol. 2003;21(3,Suppl.29):S39-S41.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. doi:10.1192/bjp.134.4.382</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55. doi:10.1111/j.2044-8341.1959.tb00467.x</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Лурия A.P. Высшие корковые функции человека. М.; 1962.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Драгунская Л.С. Изучение признаков депрессивных состояний методом «Пиктограммы». Экспериментальные исследования в патопсихологии. М.; 1976:167-174.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ковина Т.Е., Колеченко А.К., Агафонова И.Н. Коммуникативная культура и ее экспертиза. Ком. по образованию Санкт-Петербурга, С.-Петерб. ун-т пед. мастерства. СПб.: Б. и., 1996.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Зейгарник Б.В. Нарушения мышления у психически больных. М.; 1958.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Рубинштейн С.Я. Экспериментальные методики патопсихологии и опыт применения их в клинике. М.: 2004.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Зейгарник Б.В. Патология мышления. М., 1962.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Heim C, Nemeroff С. The Role of Childhood Trauma in the Neurobiology of Mood and Anxiety Disorders: Preclinical and Clinical Studies. Biol Psychiatry. 2001;49(12):1023-1039. doi:10.1016/s0006-3223(01)01157-x</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Вельтищев Д.Ю., Марченко А.С., Серавина О.Ф., Ковалевская О.Б., Лисицына Т.А. Аффективно-стрессовая модель депрессии: практическое внедрение в ревматологической практике. Психиатрия и психофармакотерапия. 2009;11(5):17-22.</mixed-citation></ref></ref-list></back></article>
